MindBio Therapeutics Corp.

Research MindBio Therapeutics Corp. (WF60) on Bullrun: market cap EUR 1.79M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerWF60
• ExchangeF
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 1.79M
• Financial periodQ4 2025
• Net income-EUR 2.42M
• Free cash flow-EUR 764.50K

Valuation Snapshot

latest market cap is EUR 1.79M.

About MindBio Therapeutics Corp.

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines;

Frequently asked questions

What is MindBio Therapeutics Corp.'s market cap?

MindBio Therapeutics Corp.'s market capitalization is EUR 1.79M.

What does MindBio Therapeutics Corp. do?

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia.